Corporate Overview
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Our lead product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials in the fourth quarter of 2025. Our follow-on candidate, SER-270 for Tardive dyskinesia, is anticipated to enter IND enabling studies in the fourth quarter of 2025. Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
Learn More about Serina Therapeutics